These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15166033)

  • 1. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
    Pardanani A; Tefferi A
    Blood; 2004 Oct; 104(7):1931-9. PubMed ID: 15166033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
    David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
    Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
    Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
    Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
    Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
    von Bubnoff N; Gorantla SP; Engh RA; Oliveira TM; Thöne S; Aberg E; Peschel C; Duyster J
    Oncogene; 2011 Feb; 30(8):933-43. PubMed ID: 20972453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate (STI571) for myeloid malignancies other than CML.
    Krystal GW
    Leuk Res; 2004 May; 28 Suppl 1():S53-9. PubMed ID: 15036942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
    Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
    Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
    Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
    Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
    Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
    Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
    J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
    Kancha RK; von Bubnoff N; Miething C; Peschel C; Götze KS; Duyster J
    Haematologica; 2008 Nov; 93(11):1718-22. PubMed ID: 18728023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
    Giles FJ; Cortes JE; Kantarjian HM
    Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
    Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
    Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.